National Guideline Clearinghouse | Sunitinib malate for gastrointestinal stromal tumour (GIST) in imatinib mesylate resistant patients.

Guideline Title
Sunitinib malate for gastrointestinal stromal tumour (GIST) in imatinib mesylate resistant patients.

Bibliographic Source(s)
Younus J, Verma S, Franek J, Coakley N, Sarcoma Disease Site Group. Sunitinib malate for gastrointestinal stromal tumour (GIST) in imatinib mesylate resistant patients. Toronto (ON): Cancer Care Ontario (CCO); 2009 Jun 9. 19 p. (Evidence-based series; no. 11-8). [16 references]

Guideline Status

This is the current release of the guideline.

The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.

Please visit the Cancer Care Ontario Web site [http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=45741] External Web Site Policy for details on any new evidence that has emerged and implications to the guidelines.

full-text:
National Guideline Clearinghouse | Sunitinib malate for gastrointestinal stromal tumour (GIST) in imatinib mesylate resistant patients.